Mateon Therapeutics

Mateon Therapeutics is a biopharmaceutical company that looks to develop anti-vascular therapeutics for patients with cancer and optical diseases. The company was founded in 1988 in San Francisco, California, United States.

The company is developing anti-angiogenic agents, of which, some are approved by the FDA and used globally to treat cancer, as well as vascular disrupting agents for the same purpose.

Mateon Therapeutics is a biopharmaceutical company that looks to develop anti-vascular therapeutics for patients with cancer and optical diseases. The company was founded in 1988 in San Francisco, California, United States.

The company is developing anti-angiogenic agents, of which, some are approved by the FDA and used globally to treat cancer, as well as vascular disrupting agents for the same purpose.

COVID-19

With the outbreak of COVID-19, Mateon Therapeutics has launched an antiviral response program to combat the disease caused by the novel coronavirus. They are exploring therapeutic and artificial intelligence platforms to develop new coronavirus treatments. They are also advancing their efforts to fight the virus and any rare tropical diseases that may come in the near future. Mateon Therapeutics claims to have discovered some antiviral candidates and has partnered with researchers to further the progress of these candidates.

The company has also established a division for the approach of developing COVID-19 treatments as well as other future zootonic outbreaks.